Literature DB >> 35821763

Germinal Centre-Related Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Report of a Remission Case.

Fang Liu1, Fei Qi1, Xiuying Zhang1, Mei Cao1, Shiguang Peng1.   

Abstract

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LTs) is a rare and the most aggressive type of the cutaneous B-cell lymphoma with poor prognosis and low therapeutic response. It mostly affects elderly women, with a 5-year survival rate of 50% if not efficiently treated. We present a 28-year-old male patient with indolent PCDLBCL-LT who reached nearly 100% clearance after six rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy sessions.
© 2022 Liu et al.

Entities:  

Keywords:  doxorubicin; leg type; prednisone (R-CHOP); primary cutaneous diffuse large B-cell lymphoma; remission; rituximab plus cyclophosphamide; vincristine

Year:  2022        PMID： 35821763      PMCID： PMC9271285          DOI： 10.2147/CCID.S373937

Source DB:  PubMed          Journal:  Clin Cosmet Investig Dermatol        ISSN： 1178-7015


  8 in total

Review 1.  Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification.

Authors:  Andrea Luísa Suárez; Melissa Pulitzer; Steven Horwitz; Alison Moskowitz; Christiane Querfeld; Patricia L Myskowski
Journal:  J Am Acad Dermatol       Date:  2013-09       Impact factor: 11.527

Review 2.  The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Authors:  Rein Willemze; Lorenzo Cerroni; Werner Kempf; Emilio Berti; Fabio Facchetti; Steven H Swerdlow; Elaine S Jaffe
Journal:  Blood       Date:  2019-01-11       Impact factor: 22.113

3.  MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes.

Authors:  Kikkeri N Naresh
Journal:  Haematologica       Date:  2007-02       Impact factor: 9.941

Review 4.  Cutaneous B-cell lymphomas: Update on diagnosis, risk-stratification, and management.

Authors:  Paolo Fava; Gabriele Roccuzzo; Silvia Alberti-Violetti; Vieri Grandi; Alessandro Pileri; Nicola Pimpinelli; Emilio Berti; Pietro Quaglino
Journal:  Presse Med       Date:  2022-01-11       Impact factor: 1.228

5.  Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.

Authors:  Robert M Kraft; Stephen M Ansell; Jose C Villasboas; N Nora Bennani; Yucai Wang; Thomas M Habermann; Gita Thanarajasingam; Scott C Lester; William Macon; David J Inwards; Luis F Porrata; Ivana N Micallef; Thomas E Witzig; Carrie A Thompson; Patrick B Johnston; Grzegorz S Nowakowski; Yi Lin; Jonas Paludo
Journal:  Hematol Oncol       Date:  2021-08-28       Impact factor: 5.271

Review 6.  Primary cutaneous diffuse large B-cell lymphoma, leg type: diagnostic considerations.

Authors:  Alexandra C Hristov
Journal:  Arch Pathol Lab Med       Date:  2012-08       Impact factor: 5.534

7.  Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France.

Authors:  Florent Grange; Pascal Joly; Coralie Barbe; Martine Bagot; Stéphane Dalle; Saskia Ingen-Housz-Oro; Eve Maubec; Michel D'Incan; Caroline Ram-Wolff; Sophie Dalac; Isabelle Templier; Eric Esteve; Gaëlle Quereux; Laurent Machet; Marion Leduc; Olivier Dereure; Liliane Laroche; Philippe Saiag; Béatrice Vergier; Marie Beylot-Barry
Journal:  JAMA Dermatol       Date:  2014-05       Impact factor: 10.282

Review 8.  Primary Cutaneous B-Cell Lymphomas: An Update.

Authors:  Paola Vitiello; Antonello Sica; Andrea Ronchi; Stefano Caccavale; Renato Franco; Giuseppe Argenziano
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.